The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study
Wenzhou, Zhejiang, 325000, China
NCT Number: NCT04672707
This clinical study is about increasing the dosage of bromine hexane hydrochloride to safety volume and continue to give it frequently in the new crown virus treatment could improve the efficacy.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Wenzhou, Zhejiang, 325000, China
The purpose is to study the pharmacokinetic characteristics and safety of bromine hexane hydrochloride in healthy adults after oral administration of bromine hexane hydrochloride tablets. Then to explore the mechanism related to the role of transmembrane serine proteases (TMPRSSs) through the study, and to provide the basis for the clinical rational administration of bromine hexane hydrochloride tablets.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
*The main components of the test drug: bromine hexane hydrochloride, excipients: starch, lactose, magnesium stearate.
32 mg
Time frame: up to 48 hours
Maximum observed concentration
Time frame: up to 48 hours
16 hour dosing period; 3 dosing periods each separated by 2 day washout
Time frame: up to 48 hours
16 hour dosing period; 3 dosing periods each separated by 2 day washout
Time frame: up to 48 hours
The proportion of the AUC (AUC to infinity) from the last point until we theoretically extrapolate to infinity
Time frame: 2 to 2.5 hours
16 hour dosing period; 3 dosing periods each separated by 2 day washout
Time frame: up to 48 hours
Apparent clearance rate
Time frame: up to 48 hours
Apparent volume of distribution
Time frame: 5 hour
16 hour dosing period; 3 dosing periods each separated by 2 day washout
Time frame: up to 48 hours
Terminal disposition rate constant
Second Affiliated Hospital of Wenzhou Medical University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07560150
Insulin Aspart, Pharmacodynamics
Chula Vista, California, United States
View Trial DetailsNCT05142592
Pharmacokinetics, Safety Issues
Portland, Oregon, United States
View Trial DetailsNCT03911050
Human Health, Pharmacokinetics
Kannapolis, North Carolina, United States
View Trial DetailsNCT05328778
Pharmacokinetics
Guangzhou, Guangdong, China
View Trial Details